News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Remetirom on Liver-Related OUtcomes in Patients with Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH OUTCOMES)

Study Status:

Open for enrollment

Contact Information:

(956) 362-2378

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

To determine the effect of randomized, once-daily, oral administration of 80 mg resmetirom versus matching placebo on patients as measured by time to experiencing a first adjudicated Composite Clinical Outcome event, defined as any of the following: all-cause mortality, liver transplant, and significant hepatic events including hepatic decompensation events (ascites, hepatic encephalopathy, or gastroesophageal variceal hemorrhage) and confirmed increase of Model for End-stage Liver Disease (MELD) score from <12 to ≥15.


Principal Investigator
Fernando Membreno, MD
John Rodriguez
Madrigal Pharmaceuticals, Inc.
Type of Trial
© 2024 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram